CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site

[October 12, 2017]

Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site

EAST RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.

The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2,800 liter hydrogenator and 1,500mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.

�We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API businss as patents on these begin to expire,� commented Aldo Magnini, Managing Director, Cambrex Milan. �This investment is consistent with the Cambrex strategic plan to increase the company�s small molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.�

This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24M, 4,500 sq. ft. highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.�The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.� For more information, please visit www.cambrex.com

Contact:�
Alex Maw�
Director, Marketing and Communications�
Tel: +44 7803 443 155�
Email: alex.maw@cambrex.com��

Primary Logo


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter

infoTECH Whitepapers